Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1461-1480 of 1,743 trials

Sublingual Vaccine: Trained Immunity Study

We are investigating whether a new sublingual vaccine can boost the immune system's response in blood cells. This study aims to understand its effects on trained immunity.

Healthy Participants>2 yearsSafety phase (I)Efficacy phase (II)

Hemophilia A: Innovative Treatment Approaches for Patients with Inhibitors

We are exploring various treatment methods for individuals with Hemophilia A who have inhibitors. The goal is to see how well these treatments reduce bleeding and improve health outcomes.

Hemophilia A>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematology

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Head and Neck Cancer: Niraparib and Dostarlimab Study

We are studying the effects of Niraparib and Dostarlimab combined with chemotherapy and radiotherapy in patients with locally advanced head and neck cancer. The goal is to see if this combination improves treatment outcomes compared to standard approaches.

Squamous Cell Carcinoma of the Head and Neck>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Preventing Infections in ICU Patients with Interferon Gamma

We are studying whether interferon gamma can help prevent secondary infections in ICU patients with weakened immune systems. This research may improve recovery and reduce hospital stays.

Sustained Immunosuppression>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Stage IV NSCLC: Osimertinib with Chemotherapy

We are studying the combination of osimertinib and chemotherapy for patients with stage IV non-small cell lung cancer who have atypical EGFR mutations. The goal is to evaluate its effectiveness, safety, and impact on quality of life.

Stage IV Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Metastatic Non-Squamous Non-Small Cell Lung Cancer: Visugromab and Nivolumab Study

We are investigating whether a new treatment combining visugromab and nivolumab with or without docetaxel can improve outcomes for patients with metastatic non-squamous non-small cell lung cancer. This study will help us understand its effectiveness and safety compared to standard treatments.

Metastatic Non-Squamous Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteOncology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alagille Syndrome: Long-Term Study of Livmarli

We are examining the long-term safety and effectiveness of Livmarli in patients with Alagille Syndrome. This study will help us understand how well the treatment works and its tolerability over time.

Alagille Syndrome>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyHepatologyInternal Medicine

Head and Neck Cancer: Nivolumab and Ipilimumab Study

We are studying the effects of nivolumab alone and in combination with ipilimumab after surgery for head and neck cancer. This trial aims to see if these treatments can help patients stay cancer-free and how they affect quality of life.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: MK-3120 Treatment Study

We are testing a new treatment called MK-3120 for people with advanced solid tumors to see how safe it is and if it can help reduce tumor size.

Advanced Solid Tumor Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Hypochondroplasia: Infigratinib for Growth

We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.

Hypochondroplasia>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Triple-Negative Breast Cancer: Sacituzumab Tirumotecan Study

We are studying a new treatment for people with previously untreated triple-negative breast cancer. This trial compares a new drug alone and with another medication against standard treatment to see which works better.

Triple Negative Breast Cancer (TNBC)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

B-Cell Malignancies: MB-CART2219.1 Therapy

We are testing a new CAR T-cell therapy for adults and children with relapsed or refractory B-cell cancers. The study aims to find the right dose and evaluate its safety and effectiveness.

Relapsed/Refractory Lymphoma or ALL>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Ovarian Cancer: Olaparib Maintenance Therapy

We are studying the effects of Olaparib as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer. This trial aims to understand its safety and how it may improve patient outcomes.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Rheumatoid Arthritis: Spironolactone Study

We are investigating whether spironolactone can help reduce symptoms in people with active rheumatoid arthritis. The study will also monitor safety and other health indicators.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Allergic Rhinitis: Beltavac® Immunotherapy

We are studying the effectiveness and safety of Beltavac®, a new immunotherapy, for people with allergic rhinitis caused by house dust mites. The trial will also look at how it affects allergy symptoms and overall quality of life.

House Dust Mite Allergy>2 yearsConfirmation phase (III)Investigational MedicinesAllergologyOphthalmologyOtolaryngology

Diffuse Large B-Cell Lymphoma: Polatuzumab Vedotin with R-CHP

We are studying whether a new treatment combining polatuzumab vedotin with standard chemotherapy helps patients with diffuse large B-cell lymphoma live longer without disease progression compared to the current standard treatment.

Diffuse Large B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Lymphoma Treatment: Loncastuximab Tesirine

We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.

B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology